Meet the Team
Our team combines a deep level of scientific and industry experience with a strong commitment to making an impact and saving lives with the innovative work we do to address infectious diseases.
Colin Broom joined Nabriva Therapeutics in August 2014. Over the past 30 years, he has been involved in all stages of drug development and commercialization. Most recently, he served as Chief Scientific Officer at ViroPharma, Inc., (now Shire). Previous positions have included a range of leadership positions with Amgen, Hoechst Marion Roussel (now Sanofi), SmithKline Beecham, and Glaxo (now GlaxoSmithKline). He has a BS in Pharmacology from University College, London and a Bachelor of Medicine and Surgery degree from St. George’s Hospital Medical School, London. He is a member of the UK Royal College of Physicians and a fellow of the Faculty of Pharmaceutical Medicine.
Robert Crotty joined Nabriva Therapeutics in June 2017. He has over a decade of experience in the pharmaceutical and biopharmaceutical industries, most recently as Vice President, General Counsel, Chief Compliance Officer, and Secretary at Vernalis Therapeutics, Inc. Robert has a broad legal skill set with experience in corporate governance, securities filings, financing, business development, corporate law, and commercial compliance. Previously, he worked in the life sciences industry with positions at Dendreon Corp., NPS Pharmaceuticals, and ImClone Systems Inc. After law school, Robert worked at two law firms, Morgan, Lewis & Bockius and Norton Rose Fulbright.
Mr. Crotty obtained his law degree from the University of Pennsylvania and his undergraduate degree from Princeton University.
Steven Gelone joined Nabriva Therapeutics in December 2014. Over the past 20 years, Steve has been involved in all stages of drug development and commercialization. He has served as Head of Clinical Research and Development at Spark Therapeutics, as well as Vice President of Development at ViroPharma Inc., (now Shire). Previous roles include leadership positions with GSK, Vicuron Pharmaceuticals, and Temple University Schools of Pharmacy and Medicine. He has a Bachelor of Sciences and Doctorate in Pharmacy degree from Temple University in Philadelphia.
Francesco Maria Lavino joined Nabriva Therapeutics in July 2017, bringing nearly two decades of pharmaceutical sales and marketing experience to his role. The last half of his career has been focused on anti-infective medications administered primarily in the hospital setting. He most recently served as AVP, Global Brand Leader Anti-Infective Portfolio at Merck & Co. Inc. (known as MSD outside the United States), where he was responsible for the development and implementation of the global marketing strategy for the whole Merck anti-bacterial portfolio. Prior to this role, Francesco was Vice President of International Marketing for the Anti-Infectives Portfolio at Cubist Pharmaceuticals, held various roles at Merck including global brand leadership for the company’s antifungal portfolio and positions in marketing and sales, both at regional and country levels. Francesco began his career in pharmaceutical sales at UCB Pharma and 3M in Italy. He has a BA in Pharmacy from the Federico II University of Napoli, Italy and an MBA from SDA Bocconi School of Management in Milan, Italy.
Gary Sender has over 25 years of financial leadership experience in the pharmaceutical and biopharmaceutical industries, most recently as CFO and Executive Vice President at Synergy Pharmaceuticals. From 2009 to 2015,
Mr. Sender served as Senior Vice President, Finance at Shire plc. supporting its Specialty Pharmaceuticals business and subsequently its Global Commercial businesses. He was responsible for financial management and support of all commercial areas of Shire’s $6 billion Specialty Pharmaceutical and Rare Disease businesses, with an emphasis on resource allocation, financial forecasting, business cases, and M&A. Prior to joining Shire, he was the founding CFO of Tengion, a biotechnology company in the field of Regenerative Medicine. Mr. Sender spent 15 years in a number of leadership roles within Merck, including Investor Relations, M&A Finance, Treasury and Divisional Financial Management. Mr. Sender holds a bachelor’s degree in Finance and Information Systems from Boston University and an MBA in Industrial Administration with a concentration in Finance from Carnegie-Mellon University.
David Garrett joined Nabriva Therapeutics in November 2015. He held previous finance roles with Covis Pharma, Auxilium, Shire, and ViroPharma Inc. Dave started his career in public accounting with KPMG and is a Certified Public Accountant. He received his Bachelor of Science and MBA degrees from Villanova University. He is also a member of the Financial Executives International, American Institute of Certified Public Accountants, and Pennsylvania Institute of Certified Public Accountants.
Leanne Gasink joined Nabriva Therapeutics in November 2015. Before working in the biopharmaceutical industry, Leanne was the Associate Hospital Epidemiologist and Co-Director of the Antimicrobial Stewardship Program at the Hospital of the University of Pennsylvania. Since 2009, she has focused on the development of treatments for infections due to multi-drug resistant bacteria. She previously held positions at AstraZeneca, where she played a leadership role in the late-stage development and subsequent approval of Ceftazadime-avibactam. Leanne has a BS degree from the Pennsylvania State University and an MD and MS in Clinical Epidemiology degree from the University of Pennsylvania. She completed her Internal Medicine and Infectious Diseases training at the University of Pennsylvania.
Werner Heilmayer joined Nabriva Therapeutics in February 2006. Having worked for almost 20 years in the pharmaceutical and biotech industry, Werner has gained significant experience in drug development and intellectual property. He has a strong track record in patent filing and is co-inventor of more than 10 international filed patent applications. Before joining Nabriva, Werner was the Head of Chemistry of Sandoz's discovery unit. Werner played a major role in the Nabriva spin-off from Sandoz and served Nabriva as Head of Chemistry, Manufacturing, Controls and Intellectual Property before he was appointed Vice President in June 2012. He holds a PhD in Organic Chemistry.
Ernest Kelly joined Nabriva Therapeutics full time in June 2016. Over the past 44 years, Ernie has been involved in all stages of pharmaceutical development and commercialization, most recently as Vice President, Quality at Shire plc. Previous roles include leadership and technical positions in Quality and Compliance with ViroPharma Inc. (now Shire), Cephalon, Bio-Technology General Corp., Rhone Poulenc Rorer (now Sanofi), Merck, and McNeil pharmaceutical companies. Ernie has been active in pharmaceutical trade associations and is a past chair of several PhRMA Technical Committees, past industry representative on USP Aerosol Advisory Panels, and a past Adjunct Professor of Pharmaceuticals at Temple University, School of Pharmacy. He has a BA in Chemistry from Millersville University and a PhD in Physical Chemistry from Villanova University.
Thomas Lembck joined Nabriva Therapeutics full time in July 2015. For 13 years, he led the IT and facility teams at ViroPharma Inc., building a global organization to support the company’s rapid growth and supported the company’s acquisition transition into Shire plc. Prior to ViroPharma, he worked with VisAlign, where he led various teams and projects focused on information systems and strategic planning for pharmaceutical companies including Schering-Plough, Pfizer, and Merck. Thomas also has held multiple roles of escalating responsibility at Comptek Research, Raytheon, and ABB in Zurich, Switzerland. At Nabriva, he has demonstrated technology leadership by crafting the requisite strategic vision to achieve business goals by offering a unique blend of executive acumen, global team-building, and IT solutions development with strong ROI and operational effectiveness. Thomas holds an MBA from Temple University, a BS degree from Rensselaer Polytechnic Institute in Electrical Engineering, and several executive training certificates from both the Bell Leadership program at University of North Carolina and Dartmouth’s Tuck Business School.
Will Sargent joined Nabriva in September 2015, with over two decades of experience in the biopharmaceutical industry, including leadership roles for multiple product and line extension launches and as a sell-side analyst on Wall Street. Most recently, he served as Vice President, Orthopedic Business Unit at Auxilium Pharmaceuticals (now ENDO International), where he led the company's marketing and sales team advancing XIAFLEX® for the treatment of Dupuytren's contracture and the development of additional pipeline indications. Mr. Sargent received his BA in Biology from Johns Hopkins University and an MBA from the University of Washington.
SV LIFE SCIENCES
Daniel Burgess – Chairman
Mr. Burgess is Venture Partner at SV Life Sciences. Previously, he was President and CEO of Rempex Pharmaceuticals, an antibiotics company he co-founded in 2011 and subsequently sold to The Medicines Company in 2013. Prior to this, Mr. Burgess was President and CEO of Mpex Pharmaceuticals, a company that advanced an inhaled antibiotic for cystic fibrosis into Phase 3 before it was acquired by Aptalis Inc. in 2011. Previously, he served as COO and CFO of Hollis-Eden Pharmaceuticals, a public biotechnology company focused on biodefense, infectious diseases, and immune system disorders. Mr. Burgess also spent 10 years at Gensia Sicor, Inc. (acquired by Teva Pharmaceutical Industries Ltd), where he held a variety of executive-level positions with responsibility for overall finance for the company. He began his career at Castle & Cooke and Smith Barney, Harris Upham & Co. Mr. Burgess is Chairman of Atox Bio and is a board member of Cidara Therapeutics, Arsanis, Arbutus Biopharma Corp., and Pulmocide. He received a BA in Economics from Stanford University and an MBA from Harvard Business School.
Mr. Bolte currently serves as an investment advisor to HBM Partners AG, based in Zug, Switzerland. He has more than 15 years of experience in health care venture capital. Mr. Bolte was an investment manager at New Medical Technologies (NMT) AG, the first Swiss healthcare-focused venture capital firm. Since joining the private equity team at HBM Partners in 2003, he has led multiple biopharma investments. Previously, Mr. Bolte held a position in R&D management at Serono SA, Geneva. He has served on the board of directors of various private and public biotechnology companies, including Adnexus Therapeutics (acquired by BMS), Kolltan Pharmaceuticals, Newron Pharmaceuticals, PTC Therapeutics, and Ophthotech. Mr. Bolte studied biochemistry and organic chemistry at the University of Cambridge, United Kingdom and the Swiss Federal Institute of Technology in Zurich, Switzerland, where he obtained an MS in Biochemistry. He also obtained an MBA from the University of St. Gallen, Switzerland.
Ms. Bourdow has served as Senior Vice President and Chief Commercial Officer of Trevena since 2015. Previously, she was Vice President of Marketing, Reimbursement, and Operations at Cubist Pharmaceuticals, Inc. Prior to joining Cubist, she spent more than 20 years at
Merck & Co., Inc., where she held positions across several therapeutic areas including anti-infectives, acute heart failure, and pain. Ms. Bourdow holds a BA degree from Hendrix College and earned her MBA from Southern Illinois University.
NABRIVA THERAPEUTICS, PLC
Colin Broom joined Nabriva Therapeutics in August 2014. Over the past 30 years, he has been involved in all stages of drug development and commercialization. Most recently, he served as Chief Scientific Officer at ViroPharma Inc., (now Shire). Previous positions have included a range of leadership roles with Amgen, Hoechst Marion Roussel (now Sanofi), SmithKline Beecham, and Glaxo (now GlaxoSmithKline). He has a BS in Pharmacology from University College, London and a Bachelor of Medicine and Surgery degree from St. George’s Hospital Medical School, London. He is a member of the UK Royal College of Physicians and a fellow of the Faculty of Pharmaceutical Medicine.
Formerly of ZALICUS, INC.
Mark Corrigan, MD
Dr. Corrigan is former President and CEO of Zalicus, Inc. Previously, he was Executive Vice President of Research and Development at the specialty pharmaceutical company Sepracor Inc. He also spent 10 years with Pharmacia & Upjohn, most recently as Group Vice President of Global Clinical Research and Experimental Medicine. Before entering the healthcare industry, Dr. Corrigan was in academic research at the University of North Carolina at Chapel Hill School of Medicine, where he maintains a faculty appointment as Adjunct Professor in the Psychiatry Department. Dr. Corrigan served on the board of directors for Cubist Pharmaceuticals and Avanir Pharmaceuticals prior to their acquisitions by Merck and Otsuka Holdings, respectively, and he served as chairman of EPIRUS Biopharmaceuticals’ board. Dr. Corrigan holds an MD from the University of Virginia and received specialty training in psychiatry at Maine Medical Center and Cornell University.
TALBOT ADVISORS LLC
George Talbot, MD, FACP, FIDSA
Dr. Talbot, an infectious diseases physician by training, began his pharmaceutical career in anti-infective drug development at Rhone-Poulenc Rorer, later Aventis. He founded his consultancy firm, Talbot Advisors LLC, in 2000. Dr. Talbot served as Executive Vice President and Chief Management Officer of Cerexa (purchased by Forest Laboratories) and worked closely with Calixa Therapeutics (acquired by Cubist Pharmaceuticals) and Durata Therapeutics (purchased by Actavis Plc). In addition to his role on Nabriva’s board of directors, he chairs its Clinical Advisory Board. Dr. Talbot was a founding member of IDSA's Antimicrobial Availability Task Force ("Bad Bugs, No Drugs"), and he co-chairs the ABSSSI/CABP and HABP/VABP Project Teams at the Biomarkers Consortium of the Foundation of the National Institutes of Health.
Charles Rowland, Jr., CPA
Mr. Rowland is a member of the board of directors of Blueprint Pharmaceuticals and was most recently the CEO of Aurinia Pharmaceuticals. He was previously the Vice President and CFO of ViroPharma Inc., until it was acquired by Shire plc in January 2014. He has over 35 years of diversified experience in pharmaceutical operations and all areas of finance and accounting. Prior to joining ViroPharma in 2008, he was Executive Vice President and Chief Financial Officer for Endo Pharmaceuticals as well as its interim Co-CEO. He held positions of increasing responsibility at Biovail Corp., Breakaway Technologies, Pharmacia Corp., Novartis AG, and Bristol-Myers Squibb Co. He holds an MBA from Rutgers University and a BS in Accounting from Saint Joseph's University.
Mr. Webster is CFO of the gene therapy company Spark Therapeutics. He was previously Senior Vice President and CFO of Optimer Pharmaceuticals, Inc., a biotechnology company developing specialty drugs to treat gastrointestinal infections and related diseases, until its acquisition by Cubist Pharmaceuticals. Prior to this, Mr. Webster served as Senior Vice President and CFO of Adolor Corp., also acquired by Cubist. Previously, Mr. Webster served as Managing Director, Investment Banking Division, Health Care Group for Broadpoint Capital Inc. (formerly First Albany Capital). He also was co-founder, President, and CEO of Neuronyx, Inc., a biopharmaceutical company. Previously, Mr. Webster held positions of increasing responsibility, including Director, Investment Banking Division, Health Care Group, for PaineWebber Inc. Mr. Webster holds an AB in Economics cum laude from Dartmouth College and an MBA in Finance from The Wharton School of the University of Pennsylvania.
© Nabriva Therapeutics plc, Ireland Registration No. 599588, 25-28 North Wall Quay, Dublin 1, Ireland